Breaking News Instant updates and real-time market news.

SGYP

Synergy Pharmaceuticals

$5.79

-0.13 (-2.20%)

15:20
03/01/17
03/01
15:20
03/01/17
15:20

Synergy Pharmaceuticals options imply 9.4% move in share price post-earnings, above median historical move

Pre-earnings options volume in Synergy Pharmaceuticals is normal with calls leading puts 19:4. Implied volatility suggests the market is anticipating a move near 9.4%, or 53c, after results are released. Median move over the past eight quarters is 2.7%.

  • 21

    Mar

SGYP Synergy Pharmaceuticals
$5.79

-0.13 (-2.20%)

01/23/17
ROTH
01/23/17
NO CHANGE
Target $10.5
ROTH
Buy
Synergy Pharmaceuticals price target raised to $10.50 from $6.50 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Synergy Pharmaceuticals (SGYP) to $10.50 from $6.50 after the FDA approved Trulance for the treatment of adults with chronic idiopathic constipation, and due to Synergy Pharmaceuticals lowered risk profile and to better align with the valuation of its peer Ironwood Pharmaceuticals (IRWD). He reiterates a Buy rating on Synergy Pharmaceuticals' shares.
02/22/17
PIPR
02/22/17
NO CHANGE
Target $205
PIPR
Neutral
Piper physician survey a 'mixed bag' for Allergan's Linzess
Piper Jaffray analyst David Amsellem says his firm's survey of 39 physicians is a "mixed bag" for Allergan's (AGN) Linzess. The feedback from doctors suggest that the prospects for double-digit annual volume growth for Linzess over the long-term "are not nearly as strong as sentiment in the broader investor community would suggest," Amsellem tells investors in a research note. A bulk of the respondents have a favorable view of Linzess but also "misgivings regarding the incidence of diarrhea," the analyst adds. Further, Amsellem does not conclude that Synergy Pharmaceuticals' (SGYP) recently approved Trulance in chronic idiopathic constipation is the "poor man's Lizness." The lower incidence of diarrhea associated with Trulance does not necessarily mean that it is a less potent agent, the analyst contends. He keeps a Neutral rating on Allergan with a $205 price target.
02/22/17
WELS
02/22/17
NO CHANGE
WELS
Underperform
Wells thinks 50-plus salespeople just left Valeant for Synergy
Wells Fargo analyst David Maris says he asked Valeant Pharmaceuticals (VRX) whether industry speculation is true regarding the company losing 50-plus gastrointestinal salespeople to Synergy Pharmaceuticals (SGYP) following the latter's recent FDA approval. Valeant indicated that a number of salespeople have left but would not confirm how many, Maris tells investors in a research note. The analyst adds that Synergy would only comment that it has been very successful in hiring a large number of experienced salespeople. The loss of 50-plus salespeople would be another setback to the Salix/gastrointestinal salesforce at a time when prescription trends on Xifaxan are already weak, Maris contends. The analyst also learned that the son of Valeant CEO Joseph Papa joined Valeant in September 2016 as a product manager for Xifaxan, the company's largest product. Maris says Valeant acknowledged that several investors have already raised the matter. Maris has an Underperform rating on the shares, which closed the trading day down 4c to $16.35.
02/24/17
WELS
02/24/17
NO CHANGE
WELS
Wells says new Valeant is not new, calls shares overvalued
The market is underestimating Valeant Pharmaceuticals' "poor" prescription trends, reliance on price, employee turnover, execution risk on product launches, patent expiries including Xifaxan and numerous lawsuits, Wells Fargo analyst David Maris tells investors in a research note titled "Deja Valeant--We See History Repeating Itself." The stock is overvalued, and despite management wanting to talk about the "new Valeant," the company's business trends and pricing-driven model remain "old Valeant," Maris contends. He cut his Q4 earnings per share estimate for the company to $1.48 from $1.48, 2017 estimate to $5.03 from $5.14 and 2018 estimate to $5.45 from $5.91. His Q4 estimate remains well above the consensus of $1.22. Maris points out that since the new management team took over in 2016, Valeant set and then lowered guidance, raised prices on more than 50 products, missed key launch targets, had manufacturing issues and saw prescription declines continue. On the positive front, the company has sold $2.3B of assets, the analyst points out. Maris, who wrote this week that Valeant likely just lost 50-plus salespeople to Synergy Pharmaceuticals (SGYP), keeps an Underperform rating on Valeant with a $10-$13 price target range. The drugmaker closed yesterday at $16.58.

TODAY'S FREE FLY STORIES

02:45
11/21/17
11/21
02:45
11/21/17
02:45
General news
FX Update: Narrow ranges have been prevailing »

FX Update: Narrow ranges…

SPN

Superior Energy

$8.81

-0.14 (-1.56%)

21:18
11/20/17
11/20
21:18
11/20/17
21:18
Upgrade
Superior Energy rating change at SunTrust »

Superior Energy upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$78.90

-0.59 (-0.74%)

, LOW

Lowe's

$81.46

1.24 (1.55%)

20:25
11/20/17
11/20
20:25
11/20/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MDT

Medtronic

$78.90

-0.59 (-0.74%)

LOW

Lowe's

$81.46

1.24 (1.55%)

ADI

Analog Devices

$93.07

2.65 (2.93%)

DLTR

Dollar Tree

$97.11

2.5 (2.64%)

HRL

Hormel Foods

$33.40

0.28 (0.85%)

CPB

Campbell Soup

$49.93

0.21 (0.42%)

BURL

Burlington Stores

$106.55

1.82 (1.74%)

SIG

Signet Jewelers

$75.84

-0.74 (-0.97%)

DSW

DSW

$22.53

0.38 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 27

    Nov

  • 01

    Dec

  • 07

    Dec

  • 08

    Dec

  • 09

    Jan

CCLP

CSI Compressco

$5.28

-0.16 (-2.94%)

19:32
11/20/17
11/20
19:32
11/20/17
19:32
Hot Stocks
CSI Compressco names Owen Serjeant president »

CSI Compressco announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$57.62

1.13 (2.00%)

, AAPL

Apple

$169.98

-0.17 (-0.10%)

19:04
11/20/17
11/20
19:04
11/20/17
19:04
Periodicals
Applied Materials expected to purchase former Apple complex, Mercury News says »

An office complex that…

AMAT

Applied Materials

$57.62

1.13 (2.00%)

AAPL

Apple

$169.98

-0.17 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

  • 29

    Nov

FOX

21st Century Fox

$29.90

-0.58 (-1.90%)

, FOXA

21st Century Fox

$30.66

-0.49 (-1.57%)

18:21
11/20/17
11/20
18:21
11/20/17
18:21
Periodicals
Fox reaches $90M settlement over sexual harassment scandal, Reuters says »

21st Century Fox reached…

FOX

21st Century Fox

$29.90

-0.58 (-1.90%)

FOXA

21st Century Fox

$30.66

-0.49 (-1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$188.00

2.87 (1.55%)

18:19
11/20/17
11/20
18:19
11/20/17
18:19
Hot Stocks
Muddy Waters says Alibaba numbers 'obviously fake' »

Short seller Muddy Waters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANW

Palo Alto Networks

$142.53

-0.19 (-0.13%)

, CHKP

Check Point

$102.98

0.83 (0.81%)

18:15
11/20/17
11/20
18:15
11/20/17
18:15
Recommendations
Palo Alto Networks, Check Point, Fortinet analyst commentary at JPMorgan »

Palo Alto quarter…

PANW

Palo Alto Networks

$142.53

-0.19 (-0.13%)

CHKP

Check Point

$102.98

0.83 (0.81%)

FTNT

Fortinet

$40.77

0.46 (1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 07

    Dec

  • 11

    Dec

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

AMZN

Amazon.com

$1,126.31

-3.57 (-0.32%)

18:14
11/20/17
11/20
18:14
11/20/17
18:14
Hot Stocks
Amazon announces cloud software for U.S spy agencies AWS Secret Region »

Amazon announced the new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

BIVV

Bioverativ

$50.76

-5.35 (-9.53%)

, RHHBY

Roche

$30.82

1.72 (5.91%)

18:08
11/20/17
11/20
18:08
11/20/17
18:08
Recommendations
Deutsche cuts Bioverativ target to $53 after positive Roche data »

Deutsche Bank analyst…

BIVV

Bioverativ

$50.76

-5.35 (-9.53%)

RHHBY

Roche

$30.82

1.72 (5.91%)

SHPG

Shire

$141.37

-6 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 09

    Dec

  • 23

    Dec

  • 23

    Feb

CUBI

Customers Bancorp

$27.04

0.28 (1.05%)

18:04
11/20/17
11/20
18:04
11/20/17
18:04
Hot Stocks
Customers Bancorp: Flagship could raise capital in IPO transaction in 1H18 »

Customers Bancorp, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

18:04
11/20/17
11/20
18:04
11/20/17
18:04
Hot Stocks
AT&T CEO says has offered DOJ solutions that were not accepted »

Says DOJ suit throws lots…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

NGD

New Gold

$3.21

-0.02 (-0.62%)

18:02
11/20/17
11/20
18:02
11/20/17
18:02
Hot Stocks
New Gold announces sale of Peak Mines for $58M »

New Gold announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMI

Intermolecular

$1.31

0.1 (8.26%)

18:01
11/20/17
11/20
18:01
11/20/17
18:01
Hot Stocks
Intermolecular partners with SITRI to develop MtM technologies »

Intermolecular, Inc and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

  • 29

    Nov

CMCSA

Comcast

$35.83

-0.33 (-0.91%)

18:00
11/20/17
11/20
18:00
11/20/17
18:00
Initiation
Comcast initiated at Buckingham »

Comcast initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNX

Mellanox

$51.05

1 (2.00%)

17:59
11/20/17
11/20
17:59
11/20/17
17:59
Hot Stocks
Mellanox up nearly 6% after Starboard discloses a 9.8% stake in the company »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 05

    Dec

  • 06

    Dec

PLNT

Planet Fitness

$30.15

0.07 (0.23%)

17:58
11/20/17
11/20
17:58
11/20/17
17:58
Initiation
Planet Fitness initiated at DA Davidson »

Planet Fitness initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TER

Teradyne

$44.43

0.86 (1.97%)

17:57
11/20/17
11/20
17:57
11/20/17
17:57
Downgrade
Teradyne rating change at Deutsche Bank »

Teradyne downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

  • 29

    Nov

CBS

CBS

$55.93

-0.81 (-1.43%)

17:56
11/20/17
11/20
17:56
11/20/17
17:56
Periodicals
CBS News suspends Charlie Rose following sexual harassment claims, AP says 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$55.93

-0.81 (-1.43%)

17:55
11/20/17
11/20
17:55
11/20/17
17:55
Periodicals
Eight women accuse Charlie Rose of sexual harassment, Washington Post says »

Eight women have said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNX

Mellanox

$51.05

1 (2.00%)

, MRVL

Marvell

$21.59

1.3 (6.41%)

17:53
11/20/17
11/20
17:53
11/20/17
17:53
Hot Stocks
Starboard Value reports 9.8% stake in Mellanox, may seek talks »

Peter A. Feld, a…

MLNX

Mellanox

$51.05

1 (2.00%)

MRVL

Marvell

$21.59

1.3 (6.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

  • 05

    Dec

  • 06

    Dec

CDXS

Codexis

17:46
11/20/17
11/20
17:46
11/20/17
17:46
Hot Stocks
Breaking Hot Stocks news story on Codexis »

Telemark Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

17:45
11/20/17
11/20
17:45
11/20/17
17:45
Hot Stocks
AT&T CEO says giving up control of CNN is a 'non-starter' »

Says plenty of solutions…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

BBY

Best Buy

$56.35

0.52 (0.93%)

17:45
11/20/17
11/20
17:45
11/20/17
17:45
Conference/Events
Best Buy management to meet with SunTrust »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

17:43
11/20/17
11/20
17:43
11/20/17
17:43
Hot Stocks
AT&T CEO says DOJ suit 'defies logic' »

Says has offered…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.